Cyclin-dependent kinase inhibitor p21 and proliferative marker ki67 in colonic carcinoma
- 1 January 2022
- journal article
- research article
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 18 (4), 915-920
- https://doi.org/10.4103/jcrt.jcrt_712_21
Abstract
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic SocietyKeywords
This publication has 26 references indexed in Scilit:
- Retrospective Analysis of Risk Factors for Central Nervous System Metastases in Operable Breast Cancer: Effects of Biologic Subtype and Ki67 Overexpression on SurvivalOncology, 2012
- Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue SarcomasPLOS ONE, 2012
- Prevalence of p53 and p21 Expression in Colorectal Cancer: A Histopathologic Study from IranJournal of Biological Sciences, 2012
- Apoptosis in cancer: from pathogenesis to treatmentJournal of Experimental & Clinical Cancer Research, 2011
- Histological Grading of Colorectal CancerAnnals of Surgery, 2008
- Rectal Cancer StagingClinics in Colon and Rectal Surgery, 2007
- Profiling markers of prognosis in colorectal cancer.Clinical Cancer Research, 2006
- Dynamic Expression Profile of p21WAF1/CIP1 and Ki-67 Predicts Survival in Rectal Carcinoma Treated With Preoperative RadiochemotherapyJournal of Clinical Oncology, 2003
- Proliferation markersExperimental and Toxicologic Pathology, 1996
- Ki‐67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlationsThe Journal of Pathology, 1988